Bullfrog AI

Bullfrog AI

About Bullfrog AI

Simplify's Rating
Why Bullfrog AI is rated
C
Rated C on Competitive Edge
Rated B on Growth Potential
Rated D+ on Differentiation

Industries

Biotechnology

Healthcare

Company Size

11-50

Company Stage

IPO

Headquarters

Baltimore, Maryland

Founded

2017

Overview

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery is gaining traction, offering growth opportunities for BullFrog AI.
  • AI in clinical trials is becoming more prevalent, providing new avenues for BullFrog AI.
  • AI-powered data networks enhance data analytics, aligning with BullFrog AI's recent initiatives.

What critics are saying

  • The recent $5.7 million public offering led to a sharp decline in share prices.
  • The partnership with Oxfam Australia may divert focus from core business operations.
  • The launch of BullFrog Data Networks could face challenges in adoption within the medical community.

What makes Bullfrog AI unique

  • BullFrog AI uses AI and machine learning for drug development.
  • The company launched BullFrog Data Networks to revolutionize data analytics in medicine.
  • BullFrog AI has a strong advisory board with industry pioneers like Dr. John Baldoni.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$9.9M

Above

Industry Average

Funded Over

3 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Growth & Insights and Company News

Headcount

6 month growth

-9%

1 year growth

-9%

2 year growth

0%
ETF Daily News
Dec 19th, 2024
BullFrog AI Appoints Josh Blacher as Chief Financial Officer

BullFrog AI appoints Josh Blacher as Chief Financial Officer.

The Manila Times
Oct 21st, 2024
Bullfrog AI Announces Closing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million

Bullfrog AI announces closing of registered direct offering and concurrent private placement for aggregate gross proceeds of $3.13 million.

Stock Titan
Oct 18th, 2024
Bullfrog AI Announces Pricing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million | BFRG Stock News

BullFrog AI raises $3.13M in stock offering: Learn how this AI company's strategic move impacts investors and the tech landscape. Discover key details and potential market effects.

The Manila Times
Oct 15th, 2024
BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) - BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board.

AiThority
Feb 29th, 2024
BullFrog AI Appoints Globally Renowned Biomedical AI Expert Dr. Thomas W. Chittenden as Chief Scientific Officer

BullFrog AI appoints globally renowned biomedical AI expert Dr. Thomas W. Chittenden as Chief Scientific Officer.

There are no jobs for Bullfrog AI right now.

Find jobs on Simplify and start your career today

💡
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →